Bees in medicine. Antitumour royal jelly properties


In treating different pathological processes (including malign tumours) accompanied by intoxication of an organism and suppression of organism reactivity, practical medicine feels an acute need for medicines, which have a protecting effect against intoxication and stimulating effects of protective forces of an organism. Nowadays scientists work hard at searching substances of vegetable and animal origin. And bee products are of primary interest.

In the apitherapy department of Apiculture Institute named after Prokopovich in Ukraine, scientists do research work to fink out the impact of bee keeping products on tumours. We'll give the results of their research of the influence of royal jelly on the growth of experimental tumors and the spreading of cancer cells.

Royal jelly is widely used both in folk and official medicine. There are some data about antiradiation effect of royal jelly (Artuzov with co- authors, 1974), about reducing the amount of cholesterol in blood and increases phospholipids in content (Makarova, 1969), about stimulating protective body forces, by activating the production of antibody and leukocytes' phagocytic capacity ( Savtchuk with co-authors, 1974).

There is contradictory information on the problem of influence of royal jelly on the growth of tumours in medical literature. Thus, Thamura with co-authors and Kern (1988) write about antitumour effect of the royal jelly. But at the same time there is a warning that royal jelly can stimulate the growth of malign tumours. ( Potchinkova, 1995, Ludyansky, 1995)

Taking into account all the mentioned above we were interested in finding out finding out the real impact that a royal jelly can have on the growth and metastasis of experimental tumours.

Experiments were made with 220 mice of C57B/6 line and other mice hybrids F1 (CBA*57B/6). Inoculation for tumours was done by usual methods. In the biomedical research, an intraperitoneal injection was used. Absorption of royal jelly is relatively rapid with intraperitoneal injection because of the rich blood supply to the abdomen. Royal jelly was injected in native and lyophilized forms. The doses varied from 5 up to 100 mg/kg. In the case of carcinoma of lungs and adenocarcinoma 755 we could judge about the antitumour effect of royal jelly by the size of the primary tumor, the number of metastases to lungs. In the experiments with lymphoid leukemia L 1210 the animals average duration of life was a criterion of the effectiveness.

We received the following data. Royal jelly in lyophilized form (5mg/kg *14) doesn't influence the growth of lung cancer, whereas it has a definite antimetastatic effect of royal jelly ( a 54 and 71% reduction of the quantity and quality of lung metastases as compared to the animals in control groups, who were given only distilled water). Lyophilized medicine in different doses didn't influence the development of adenocarcinoma and the average longevity of life of animals with lymphoid leukemia.

Experiments with native royal jelly have shown that this bee product ( 10mg/kg*12 and 100mg/kg*12) moderately hindered the development of lung carcinoma (25-38%) and had a pronounced metastatic effect.

We also studied the ability to use royal jelly in complex therapy for treating malign tumors. Royal jelly used in combination with cyclophosphamide an antitumour preparation, which is often used for treating lung carcinoma, moderately strengthens its therapeutic effect. Thus, the mass of the tumour in combined treating 0,2 against 1,9 in cyclophosphamide treating. Lung metastases were not observed whereas in the control group of the animals who were injected only cyclophosphamide their number was 2,5%.

So frequent injections of the preparation, in different therapeutic doses hinders the growth of primary tumours and gives a more pronounced antimetastatic effect. Cyclophosphamide combined with royal jelly has a better therapeutic effect. It is worthwhile mentioning that very effective against slowly developing reinoculated tumours (ling carcinoma) and is not effective against quickly growing tumours ( lymphoid leukemia). In all the experiments the stimulation of experimental blastomas was not observed, that is very important from the point of view of oncological safety of the preparation.


English translation © Irina Yelsukova